Hatteras Venture Partners is a Durham, North Carolina–based venture capital firm founded in 2000 that invests in seed and early-stage companies in human medicine. The firm focuses on biopharmaceuticals, medical devices, and health technology, with a long-standing reputation for backing transformative healthcare innovations. Hatteras is a Registered Investment Adviser (RIA) and manages more than USD 900 million across seven venture funds.
Hatteras targets early-stage investment opportunities in biopharmaceuticals, medical devices, and health technology, with an emphasis on companies that address significant unmet medical needs in human health.
Its portfolio spans therapeutics, diagnostics, medical tools, and healthcare technology solutions.
In August 2025, Hatteras Venture Partners announced the close of over USD 200 million across two new healthcare-focused funds: Hatteras Venture Partners VII (HVP VII) and Hatteras Opportunity Fund I (HOF I).
The capital was raised from a network of institutional limited partners and family offices. HVP VII continues the firm’s focus on seed and early-stage investments, while HOF I is structured to pursue unique opportunities across the healthcare spectrum.
These funds expand Hatteras’s capacity to support innovative companies at multiple points in their development, from inception through growth stages.
Leadership
The firm is led by General Partners Clay Thorp and John Crumpler, supported by a team of experienced investors and sector specialists. Recent promotions include Ben Scruggs, Ph.D., elevated from Principal to Partner with a focus on biopharmaceuticals and tools investments, and Lauren Flickinger, promoted to Partner and Fund Manager of the Pisgah Fund, who is also a leader in building the health technology portfolio.
Investment Strategy
Hatteras Venture Partners applies a thesis-driven approach, focusing on high-impact healthcare innovations with strong scientific foundations and clear commercialization potential.
The firm partners closely with entrepreneurs, offering not only capital but also strategic guidance, operational expertise, and access to a broad healthcare network. Investments are aimed at achieving significant advances in human medicine, with an emphasis on long-term value creation.
Notable Investments
The firm’s portfolio includes:
Notable Exits
Hatteras has recorded 76 exits, including:
